Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Sanofi : Rises 2 Positions in the 2016 Access to Medicine Index

share with twitter share with LinkedIn share with facebook
share via e-mail
12/07/2016 | 07:50pm CET

In 2016, Sanofi has risen 2 positions in the Access To Medicine (ATM) Index, from 8th to 6th rank. The ATM Index analyses the top 20 research-based pharmaceutical companies on how they make medicines, vaccines and diagnostics more accessible in low- and middle-income countries.

Sanofi’s performance is well recognized this year in the two main areas, which represent 45% of the overall score and are major enablers of access:

Research & Development:

Our performance in R&D is due to a larger relevant pipeline with 28 relevant R&D projects, including several new fixed-dose combinations for treating tuberculosis and a paediatric formulation of primaquine for malaria, to high standards of transparency regarding our clinical trial data and to the sharing of intellectual property with several partners in order to accelerate research in tuberculosis, malaria and neglected tropical diseases.

Pricing, Manufacturing & Distribution:

Sanofi improved in equitable pricing. We are among the 3 companies having the best performance to meet the key criteria set by the Index for pricing strategies. Besides, we are the company leader marketing the most essential medicines and vaccines (WHO Model Essential Medicines List).

The ATM Index also recognizes our innovative approach in the field of “climate change and health” still confirmed these days with our participation to COP22 at Marrakech. For more than 2 years now, we have been investigating health- and access-related issues linked to climate change.

Finally, Sanofi is the biggest riser in the area of marketing practices and compliance, climbing 13 places into the top 5. The ATM index notably emphasizes our above-average transparency and our certification system that allows us to regularly test and update the skills of our sales agents.

Learn more about the ATM Index here.

Copyright 2016, 3BL Media LLC, source Corporate Responsibility

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
12/07 SANOFI : Rises 2 Positions in the 2016 Access to Medicine Index
12/07 SANOFI : Pasteur Receives Wellbeing Award From The Commonwealth Medical College
12/07 MANNKIND CORPORATION (NASDAQ : MNKD) Files An 8-K Completion of Acquisition or D..
12/06DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
12/06DJSANOFI : Big Pharma, Short on Blockbusters, Outsources the -2-
12/06DJSANOFI : Big Pharma, Short on Blockbusters, Outsources the Science
12/06 SANOFI : Disclosure of trading in own shares
12/06 SANOFI : Disclosure of trading in own shares
12/05 SANOFI GENZYME : Announces Start of Phase III Study of Isatuximab for Relapsed a..
12/03 MYOKARDIA : Announces Receipt of Milestone Payment from Sanofi for DCM Candidate..
More news
Sector news : Pharmaceuticals - NEC
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
12/07DJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal
12/07DJMARKET SNAPSHOT : Dow, S&P 500 Set Intraday Records, But Health-care Slumps On T..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/07 ET TU, DONALD? DRUGS DIVE : What's Going On, And What's Next
12/07 Bayer buys Boehringer's CYDECTIN vet products in U.S.
12/07 Sanofi buys $10M of insulin from MannKind under settlement agreement
12/06 Microsoft Defeats Salesforce; LinkedIn Deal Set To Close
12/06 WALL STREET BREAKFAST : World's Oldest Bank In Jeopardy
Financials (€)
Sales 2016 36 745 M
EBIT 2016 9 372 M
Net income 2016 5 436 M
Debt 2016 5 746 M
Yield 2016 3,98%
P/E ratio 2016 16,36
P/E ratio 2017 14,89
EV / Sales 2016 2,81x
EV / Sales 2017 2,83x
Capitalization 97 417 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 81,1 €
Spread / Average Target 7,4%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.20%104 405
JOHNSON & JOHNSON9.09%304 863
PFIZER INC.-2.23%191 517
ROCHE HOLDING LTD.-19.65%190 397
NOVARTIS AG-20.79%180 387
MERCK & CO., INC.14.12%166 200
More Results